Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.23.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Operating Activities:    
Net loss $ (24,339) $ (31,118)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization [note 4] 171 171
Stock-based compensation [note 8[c], note 8[e], note 8[f] and note 8[g]] 3,449 2,492
Shares issued as settlement with trade vendor 273 26
Accrued interest on SVB convertible debt [note 7] 910 863
Accretion of discount on modification of debt 268  
Changes in operating assets and liabilities:    
Grant receivable [note 3] 22 8
Prepaid expenses and other assets 618 (1,256)
Accounts payable (1,022) (429)
Accrued liabilities other 310 171
Accrued clinical liabilities (739) 3,200
Accrued compensation 22 (550)
Lease obligation [note 9] (58) (4)
Net cash used in operating activities (20,115) (26,426)
Financing Activities:    
Proceeds from exercise of warrants 227 24
Proceeds from ATM, net of issuance costs   1,499
Financing costs relating to November 2022 private placement (30)  
Proceeds from employee stock purchase plan [note 8[g]]   126
Taxes paid related to net share settlement of equity awards (220) (47)
Proceeds from May 2023 private placement, net of issuance costs 15,301  
Net cash provided by financing activities 15,278 1,602
Investing Activities:    
Purchase of property and equipment (15)  
Net cash used in investing activities (15)  
Effect of exchange rate changes on cash   (1)
Net decrease in cash, cash equivalents and restricted cash (4,852) (24,825)
Cash, cash equivalents and restricted cash at beginning of the period 24,821 43,072
Cash, cash equivalents and restricted cash at end of the period $ 19,969 $ 18,247